PROGRAM
All Times are EST
Program is subject to change
Friday, February 12, 2021
| 7:50 am | Welcome and Overview / Pre-Program Test Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Thomas A. Albini, MD |
| Session I: Imaging Normal and Non-Exudative AMD Eyes Moderators: Philip J. Rosenfeld, MD, PhD; Zohar Yehoshua, MD, MHA; Giovanni Gregori, PhD Panelists: Christine A. Curcio, PhD; James G. Fujimoto, PhD; Ruikang (Ricky) Wang, PhD; Eric M. Moult, BSc; Robyn Guymer, MBBS, PhD, FRANZCO, FAHMS; David Sarraf, MD |
|
| 8:00 | Histopathology of Basal Laminar Deposits and Bruch’s Membrane in AMD Christine A. Curcio, PhD |
| 8:15 | Ultrahigh Resolution SD-OCT in Normal Aging and AMD James G. Fujimoto, PhD |
| 8:30 | Quantitative Measurements of 3D Choroid and Choriocapillaris Using SS-OCT Ruikang (Ricky) Wang, PhD |
| 8:45 | Computational Modelling for Assessing OCT Biomarkers of Geographic Atrophy Growth Eric M. Moult, BSc |
| 9:00 | The Status of the Choriocapillaris in Nascent GA Robyn Guymer, MBBS, PhD, FRANZCO, FAHMS |
| 9:15 | Rate of Progression of iRORA to cRORA in AMD David Sarraf, MD |
| 9:30 | En Face OCT Imaging Simplifies the Detection of Pre-cRORA Lesions Philip J. Rosenfeld, MD, PhD |
| Session II: Imaging Eyes With Exudative AMD Moderators: Thomas A. Albini, MD; Luis J. Haddock, MD; Raquel Goldhardt, MD Panelists: Seung-Young Yu, MD; Usha Chakravarthy, MD; K. Bailey Freund, MD; Anat Loewenstein, MD |
|
| 9:45 | OCTA Biomarkers for CNV Secondary to AMD Seung-Young Yu, MD |
| 10:00 | Detection of Exudative AMD at Earliest Onset Yields New Information on Lesion Morphology Usha Chakravarthy, MD |
| 10:15 | Multimodal Imaging Features and Clinical Relevance of Subretinal Lipid Globules K. Bailey Freund, MD |
| 10:30 | Home OCT Based Management of Neovascular AMD Anat Loewenstein, MD |
| Session III: Emerging Therapies for Non-Exudative AMD Moderators: Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; Nicolas Yannuzzi, MD Panelists: Nadia K. Waheed, MD, MPH; Jeffrey S. Heier, MD; Charles C. Wykoff, MD, PhD; Pravin U. Dugel, MD; Cedric G. Francois, MD, PhD; Glenn J. Jaffe, MD; SriniVas R. Sadda, MD |
|
| 10:45 | Results of a Phase 1/2 Study on Gene Therapy for the Treatment of Geographic Atrophy Nadia K. Waheed, MD, MPH |
| 11:00 | C5 Inhibition With Avacincaptad Pegol for the Treatment of Geographic Atrophy Pravin U. Dugel, MD |
| 11:15 | Inhibition of Complement C3 in Geographic Atrophy With NGM621: Phase 1 Study Results Charles C. Wykoff, MD, PhD |
| 11:30 | C3 Inhibition with Pegcetacoplan for the Treatment of GA in AMD Cedric G. Francois, MD, PhD |
| 11:45 | Is it Valid to Use CAM OCT Criteria for Macular Atrophy in Interventional Non-Neovascular and Neovascular AMD Clinical Trials? Glenn J. Jaffe, MD |
| 12:00 pm | Impact of Pegcetocoplan on Progression of Nascent Atrophy in AMD SriniVas R. Sadda, MD |
| 12:15 | Update on Elamipretide for the Treatment of AMD Jeffrey S. Heier, MD |
| 12:30 | Adjourn until Saturday Feb. 13th at 8:00 am |
Saturday, February 13, 2021
| 7:50 am | Welcome and Overview Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Thomas A. Albini, MD |
| Session IV: Emerging Therapies for Exudative AMD Moderators: Thomas A. Albini, MD; Jorge A. Fortun, MD; Sander R. Dubovy, MD Panelists: Fenghua Wang, MD; David M. Brown, MD; Diana V. Do, MD; Carl D. Regillo, MD |
|
| 8:00 | The Efficacy and Safety of IBI 302, a Bispecific Antibody for the Treatment of Exudative AMD Fenghua Wang, MD |
| 8:15 | Axitinib— A Novel TKI Delivered by Suprachoroidal Injection for AMD David M. Brown, MD |
| 8:30 | KSI-301: Intravitreal Antibody Biopolymer Conjugate that Demonstrates Extended Durability in Wet AMD and Retinal Vascular Diseases Diana V. Do, MD |
| 8:45 | Port Delivery System (PDS) for Exudative AMD: Archway Phase 3 Study Results Carl D. Regillo, MD |
| 9:00 | Brolucizumab Inflammation Update Thomas A. Albini, MD |
| Session V: Gene Therapy for Exudative AMD and Diabetic Retinopathy Moderators: Janet Davis, MD; Ninel Z. Gregori, MD; Philip J. Rosenfeld, MD, PhD Panelists: Allen Ho, MD; Arshad Khanani, MD, MA; Peter A. Campochiaro, MD |
|
| 9:15 | Subretinal Gene Therapy for Exudative AMD Allen C. Ho, MD |
| 9:30 | Intravitreal Gene Therapy for Exudative AMD and Diabetic Retinopathy Arshad Khanani, MD, MA |
| 9:45 | Suprachoroidal Gene Therapy for Exudative AMD and Diabetic Retinopathy Peter A. Campochiaro, MD |
| Session VI: Dual Inhibition of Ang2 and VEGF for the Treatment of DME and Exudative AMD – An Update from the Faricimab Program Moderators: Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; Usha Chakravarthy, MD; Lawrence J. Singerman, MD Panelists: Karl G. Csaky, MD, PhD; Jeffrey S. Heier, MD; Charles C. Wykoff, MD, PhD |
|
| 10:00 | Dual Inhibition of Ang-2 and VEGF-A with Faricimab: Rationale for Ang2 Inhibition in Exudative AMD and Diabetic Macular Edema Karl G. Csaky, MD, PhD |
| 10:15 | Faricimab Phase 3 Topline Results in Diabetic Macular Edema Charles C. Wykoff, MD, PhD |
| 10:30 | Faricimab Phase 3 Topline Results in Exudative AMD Jeffrey S. Heier, MD |
| 10:45 | Discussion |
| Session VII: Diabetes, Choroiditis, Retinitis Pigmentosa and Late Breaking Reports Moderators: Harry W. Flynn, Jr., MD; Justin H. Townsend, MD; Jayanth Sridhar, MD Panelists: Quan Dong Nguyen, MD, MSc; Jennifer K. Sun, MD; Dilsher S. Dhoot, MD; Lawrence A. Yannuzzi, MD; David S. Boyer, MD; Andrew A. Moshfeghi, MD, MBA |
|
| 11:00 | AXT-107: Potential Role in Neovascular AMD, Diabetic Macular Edema, and Retinal Vein Occlusion Quan Dong Nguyen, MD, MSc |
| 11:15 | Widefield SS-OCT Imaging of Diabetic Retinopathy Harry W. Flynn, Jr., MD |
| 11:30 | Anti-VEGF in the Treatment of Nonproliferative Diabetic Retinopathy Jennifer K. Sun, MD |
| 11:45 | Correlation Between Baseline Retinal Non-Perfusion Area and Outcomes in the PANORAMA Study Dilsher S. Dhoot, MD |
| 12:00 pm | Are There Two Forms of Multiple Evanescent White Dot Syndrome (MEWDS)? Lawrence A. Yannuzzi, MD |
| 12:15 | Retinal Progenitor Cell Injections for Retinitis Pigmentosa David S. Boyer, MD |
| 12:30 | Intravitreal Hydrogel-Based Axitinib Implant (OTX-TKI) for the Treatment of Neovascular AMD: Phase 1 Trial Update Andrew A. Moshfeghi, MD, MBA |
| 12:45 | Post-Program Test and Closing Remarks |